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A B S T R A C T   
Microbiota has a role in the host blood pressure (BP) regulation. The immunosuppressive drug mofetil myco-
phenolate (MMF) ameliorates hypertension. The present study analyzes whether MMF improves dysbiosis in a 
genetic model of hypertension. Twenty weeks old male spontaneously hypertensive rats (SHR) and Wistar Kyoto 
rats (WKY) were randomly divided into three groups: untreated WKY, untreated SHR, and SHR treated with MMF 
for 5 weeks. MMF treatment restored gut bacteria from the phyla Firmicutes and Bacteroidetes, and acetate- and 
lactate-producing bacteria to levels similar to those found in WKY, increasing butyrate-producing bacteria. MMF 
increased the percentage of anaerobic bacteria in the gut. The improvement of gut dysbiosis was associated with 
an enhanced colonic integrity and a decreased sympathetic drive in the gut. MMF inhibited neuroinflammation 
in the paraventricular nuclei in the hypothalamus. MMF increased the lower regulatory T cells proportion in 
mesenteric lymph nodes and Th17 and Th1 infiltration in aorta, improved aortic endothelial function and 
reduced systolic BP. This study demonstrates for the first time that MMF reduces gut dysbiosis in SHR. This effect 
could be related to its capability to improve gut integrity due to reduced sympathetic drive in the gut associated 
to the reduced brain neuroinflammation.   
1. Introduction 
Systemic arterial hypertension is a complex, multifactorial and 
multisystem disorder influenced by genetic and environmental factors, 
and the most important modifiable risk factor that contributes signifi-
cantly to worldwide cardiovascular morbidity and mortality. The pre-
cise cause of elevated blood pressure (BP) often cannot be determined 
and its identification is still challenging. Hypertension appears to have a 
complex association with the state of the sympathetic nervous system, 
endothelial dysfunction, cardiovascular remodelling and renal 
dysfunction. Moreover, emerging evidence indicates that immune sys-
tem dysfunction is an important factor in the pathogenesis of hyper-
tension [1]. In fact, T cell activation modulates the development of 
hypertension induced by both angiotensin II or deoxicorticosterone ac-
etate (DOCA)-salt [2]. 
Recently, an imbalance in the gut microbiota composition relative to 
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the healthy state, termed dysbiosis, has been associated with hyper-
tension [3–6]. The characteristics of dysbiosis in spontaneous hyper-
tensive rats (SHR) were decrease in the microbial richness, marked 
increase in the Firmicutes/Bacteroidetes (F/B) ratio, and decrease in 
acetate- and butyrate-producing bacteria and an increase in the 
lactate-producing bacterial population [3,5,7–9]. Bacterial derived 
short chain fatty acids (SCFAs) are involved in BP regulation [9,10]. 
Studies using fecal microbiota transplantation have demonstrated that 
gut flora from hypertensive animals and human increased BP, showing a 
cause-effect relationship [5,11], albeit the mechanisms involved in BP 
regulation by the microbiota have not been fully elucidated. Gut dys-
biosis was associated to low intestinal integrity, which facilitates the 
translocation across the intestinal epithelium of bacteria and their en-
dotoxins and metabolites, leading to CX3CR1+ cells (dendritic cells and 
macrophages) activation and migration to lower intestinal tract draining 
lymph nodes, promoting T cells activation [12]. 
The microbiome has a crucial part in the induction, maturation and 
maintenance of the host immune system. Interestingly, inhibition of T 
cell activation and T helper (Th)17 differentiation inhibited the hyper-
tensive effect induced by dysbiotic microbiota from SHR, showing that 
immune system dysregulation induced by the gut microbiota may be, at 
least partially, responsible for causing hypertension [5]. However, 
immunosuppressive drugs, such as tacrolimus and mofetil mycopheno-
late (MMF) differently affect BP, whereas tacrolimus increases BP 
[13–15], MMF reduces it [16–21]. Tacrolimus reduces the overall 
number of T cells because of its inhibitory effect on calcineurin, the 
remaining T cells differentiate into Th17, which releases the potent 
proinflammatory cytokine interleukin (IL)-17, leading to endothelial 
dysfunction and hypertension [22]. MMF is a prodrug of mycophenolic 
acid (MPA), an inhibitor of inosine 5′-monophosphate dehydrogenase. 
This drug also depletes proliferating B and T lymphocytes due to its 
ability to rate-limit enzymes in de novo synthesis of guanosine nucleo-
tides. MMF was able to prevent the development of hypertension in 
SHRs, Dahl salt-sensitive rats and DOCA-salt due to this pharmacological 
inhibition of B and T cells proliferation [16–21]. However, MMF is not a 
blood pressure lowering drug. Animal studies and clinical reports link-
ing this drug to lower blood pressure occur only when immune-mediated 
renal disease coexists [23]. In contrast with tacrolimus, MPA in vitro 
inhibits Th17 differentiation in activated human peripheral blood 
mononuclear cells [24,25], and human CD4 cells, and in vivo in renal 
transplant patients [26], which could be involved in BP regulation. In 
fact, MMF decreased circulating and renal T cells in SHR, although MMF 
reduced both T cell subtypes, Th17 and T-regulatory (Tregs) [27]. 
Recently, tacrolimus induced-hypertension was linked to gut dysbiosis 
and the capacity of gut microbiota from tacrolimus-mice to induce an 
elevation in BP was a result of an elevation in Th17 populations and a 
reduction in Treg populations [28]. Similarly, it has been described that 
MMF influences the gut microbiome in renal transplant patients [29–32] 
and rodents [33]. Moreover, MMF treatment causes dynamic changes in 
the composition of the intestinal microbiota that may be a targetable 
driver of the gastrointestinal side-effects of MMF [34,35]. Furthermore, 
under normotensive conditions, chronic MMF treatment did not signif-
icantly change the overall gut microbial composition, and phyla, fam-
ilies and genera proportion [36]. However, it is unknown whether the 
modulation of the immune system by MMF normalizes the gut dysbiosis 
under hypertensive conditions. Thus, the aim of this study was to 
analyze the effects of MMF in the gut microbiota and T-cell populations 
in a genetic model of hypertension. 
2. Materials and methods 
2.1. Animals and experimental groups 
The experiments performed in this study followed the European 
Union regulations and requirements on the protection of animals used 
for scientific purposes. All protocols were approved by the Ethics 
Committee of Laboratory Animals of the University of Granada (Spain; 
permit number 03-CEEA-OH-2013). Animal studies are reported in 
compliance with the ARRIVE guidelines [37]. Twenty weeks old male 
SHR and Wistar Kyoto (WKY) rats from Envigo (RRID:RGD5508396, 
Barcelona, Spain) were purchased for this study. The animals were 
arbitrarily allotted into three groups: a) untreated WKY (WKY, 1 mL of 
tap water/day, n = 8), b) untreated SHR (SHR, 1 mL of tap water/day, n 
= 8), and c) and SHR treated with MMF (SHR-MMF, 20 mg/Kg/day by 
gavage for 5 weeks, n = 8). Rats were kept in individual and ventilated 
cages. Food and water intake were recorded daily for all groups. During 
the experimental period, rats had free access to tap water and chow. 
Body weight was measured every week. MMF treatment was stopped 2 
days before the end of the experiments, to study its long-term effects 
without the involvement of acute administration effects. 
2.2. Blood pressure measurements 
A 2-week adaptation period for vehicle administration and systolic 
blood pressure (SBP) measurements was established prior to the start of 
any experimental procedures. The evolution of SBP was recorded every 
week at room temperature by tail-cuff plethysmography as described 
previously [8,9,38]. 
2.3. Cardiac and renal weight indices 
At the experimental end point, the animals fasted for 18 h and were 
anesthetized with 2.5 mL/kg equitensin (i.p.). Blood was collected from 
the abdominal aorta. Then, the animals were euthanised via exsangui-
nation. The heart was taken out and weighed, and then divided into the 
left ventricle and the right ventricle plus atria. All collected samples 
were frozen in liquid nitrogen and subsequently preserved at -80 ◦C. 
2.4. Plasma determinations 
Ice was used to cool blood samples, which were centrifuged at 3500 
rpm at 4 ◦C for 10 min, then the plasma is frozen at − 80 ◦C. According to 
the manufacturer’s instructions, the Amebocyte Lysate Chromogenic 
Endotoxin Quantitative Kit (Lonza, Valais, Switzerland) was used to 
measure the plasma lipopolysaccharide (LPS) concentration. 
2.5. Vascular reactivity studies 
Thoracic aortic ring-shaped segments (3 mm) were obtained and 
placed in organ chambers filled with Krebs solution (composition in 
mmol/L: CaCl2 2, glucose 11, KCl 4.75, KH2PO4 1.2, MgSO4 1.2, NaCl 
118 and NaHCO3 25) as described in previous articles [39]. The 
concentration-relaxation responses to acetylcholine (10− 9 -10-5 mol/L) 
were analyzed in aorta pre-contracted with phenylephrine (1 μmol/L). 
Nitroprusside concentration-relaxation responses (10− 9–10− 6 mol/L) 
were performed in the dark in aortic rings denuded from endothelium 
pre-contracted with 1 μmol/L phenylephrine. In some rings, acetylcho-
line responses were studied after incubation with NG -nitro-L-arginine 
methyl ester (L-NAME, a non-selective competitive inhibitor of nitric 
oxide synthase, 10− 5 mol/L) or apocynin (non-selective inhibitor of 
NADPH oxidase activity, 10− 4 mol/L) for 30 min. Relaxant responses 
were represented as a percentage of precontraction tension levels. 
2.6. NADPH oxidase activity 
As previously described [40], to determine the NADPH oxidase ac-
tivity in the intact aortic ring, we utilized a lucigenin-enhanced chem-
iluminescence assay. The aortic rings of all experimental groups were 
incubated in a physiological salt solution (pH 7.4) containing HEPES 
with the following composition (in mmol/L) at 37 ◦C for 30 min: CaCl2 
1.2, glucose 5.5, HEPES 20, KCl 4.6, KH2PO4 0.4, MgSO4 1, NaCl 119, 
NaHCO3 1 and Na2HPO4 0.15. Adding NADPH (100 μmol/L) to the 
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buffer containing the aortic ring, and automatically injecting lucigenin 
(5 μmol/L). NADPH oxidase activity was determined by measuring 
luminescence for 200 s periods in 5-s intervals in a scintillation counter 
(Lumat LB 9507, Berthold, Germany) and calculated by subtracting the 
basal values from those obtained in the presence of NADPH and 
expressed as RLU (relative light units)/min per mg of tissue for aortic 
rings. 
As mentioned earlier [41], the NADPH oxidase activity in the para-
ventricular nucleus (PVN) homogenate was measured by the dihy-
droethidium (DHE) fluorescence assay in a microplate reader. A solution 
of fresh homogenate (10 μg protein) with DHE (10 μmol/L) and deox-
yribonucleic acid (DNA, 1.25 μg/mL) in PBS (100 mmol/L), pH 7.4, 
containing 100 μmol/L DTPA and NADPH (50 μmol/L) to a final volume 
of 120 μL, was incubated for 30 min at 37 ◦C in the dark. The total 
fluorescence was tracked in a fluorescence spectrophotometer (Fluo-
rostart, BMG Labtechnologies, Offenburg, Germany) using a rhodamine 
filter (excitation 490 nm, emission 590 nm) in a microplate reader. 
2.7. Measurement of ex vivo vascular reactive oxygen species (ROS) 
levels and of intracellular ROS concentrations in the brain 
DHE, an oxidative fluorescent dye, was used to localize and quantify 
ROS in aortic segments in situ, as previously described [40]. To sum-
marize, aorta segments were included in optimum cutting temperature 
compound medium (Tissue-Tek; Sakura Finetechnical, Tokyo, Japan), 
snap frozen, and cut into 10 μm thick sections in a cryostat (Microm 
International Model HM500 OM). Sections where then placed on slides. 
These slides were incubated at room temperature for 30 min with DHE 
(10 μmol/L) in the dark, counterstaining with the nuclear stain 4,6-dia-
midino-2-phenylindole dichlorohydrate (DAPI, 300 nmol/L) and 
examined on a fluorescence microscope (Leica DM IRB, Wetzlar, Ger-
many) in the following 24 h period. Images of the segments were then 
aquired and ethidium and DAPI fluorescences were quantified with the 
program ImageJ (version 1.32j, NIH, http://rsb.info.nih/ij/). ROS pro-
duction levels were expressed as the ratio of ethidium/DAPI 
fluorescence. 
ROS levels were measured in brain PVN homogenates via the fluo-
rescent probe 5-(and-6-)chloromethyl-2′-7′-dichlorodihydrofluorescein 
diacetate (CM-H2DCFDA). The homogenates were prepared in lysis 
buffer composed of 50 mmol/L Tris− HCl (pH 7.4) containing 10 μg/mL 
aprotinin, 0.1 mmol/L EDTA, 0.1 mmol/L EGTA, 10 μg/mL leupeptin 
and 1 mmol/L PMSF. The samples (10 μg of protein) were incubated in 
96-well plates with 5 μmol/L CM-H2DCFDA for 30 min at 37 ◦C, in the 
absence or presence of apocynin, a NADPH oxidase inhibitor (50 μmol/ 
L). The intensity of the fluorescent signal was measured using a spec-
trofluorimeter (Fluorostart, BMG Labtechnologies, Offenburg, Ger-
many) [41]. 
2.8. Lymphocyte conditioned media 
Mesenteric lymph nodes (MLN) were excised from the animals and 
meticulously mashed with slides dipped in sterile PBS in order to reduce 
friction. The suspensions obtained were then filtered with 70 μm cell 
strainers. Following a previously detailed protocol [42], 5 μg/mL 
Concanavalin A was used in RPMI 1640 with 10 % fetal bovine serum 
and 2 mmol/L glutamine to stimulate total lymphocytes from lymph 
nodes (2.5 × 106/mL), and 48 mL of 10 mmol/L 6-HEPES, 100 U/mL 
penicillin, 100 g/mL streptomycin and 50 μmol/L β-mercaptoethanol in 
a 25 mL flask for 48 h. After centrifugation, the lymphocyte conditioned 
media were stored at -80 ◦C until use. IL-10 and IL-17a levels and other 
cytokines were measured via ELISA. 
2.9. Flow cytometry 
MLN were obtained from all animals and mashed with slides dipped 
in sterile PBS to decrease friction. The resulting solutions were filtered 
through 70μM cell strainers. 1 × 106 cells were counted for each panel. 
Cells were stimulated with 50 ng/mL PMA plus 1 μg/mL ionomycin for 
30 min, and then incubated with a protein transport inhibitor (BD 
GolgiPlugTM) to enhance detection and staining of intracellular cyto-
kines for 4 h at 37 ◦C. Then, cells were transferred to polystyrene tubes. 
The cells were blocked with anti-CD32 (clone D34-485) to avoid non- 
specific binding to Fc-gamma receptors, concomitantly, samples were 
stained with a viability dye (LIVE/DIED® Fixable Aqua Dead cell Sain 
Kit, Molecular Probes, Oregon, USA) for 20 min at 4 ◦C in the dark. Then, 
cells were incubated for 30 min at 4 ◦C for surface staining with mAbs 
anti-CD4 (PerCP-Vio700, clone REA482, Miltenyi Biotec, Bergisch 
Gladbach, Germany), anti-CD45 (APC, clone RA3-6B2 BD Pharmi-
genTM, New Jersey, USA. The lymphocytes were then fixed and per-
meabilized simultaneously with the Fix/Perm Fixation/ 
Permeabilization kit (eBioscience, San Diego, USA) and intracellular 
staining was achieved with mAbs anti-forkhead box P3 (FoxP3) (PE, 
clone FJK-16 s, eBioscience, San Diego, USA), anti-IL-17A (PE-Cy7, 
clone eBio17B7, eBioscience, San Diego, USA) for 30 min at 4 ◦C in the 
dark. Samples were analyzed using a CANTO II flow cytometer (BD 
Biosciences) and the data were analyzed with FlowJo software (Tree 
Star, Ashland, OR, USA) [43]. 
2.10. Gene expression analysis 
The analysis of gene expression in aorta, colon, brain PVN, or MNL 
was performed by RT-PCR, as previously described [40]. Thus, total 
RNA from all samples was obtained by homogenization using TRI Re-
agent® following the manufacturer’s protocol. RNA levels were quan-
tified with the Thermo Scientific NanoDropTM 2000 Spectrophotometer 
(Thermo Fisher Scientific, Inc., Waltham, MA, USA) and 2 μg of RNA 
from all samples were reverse transcribed into cDNA using oligo(dT) 
primers (Promega, Southampton, UK). Polymerase chain reaction was 
carried out with a Techne Techgene thermocycler (Techne, Cambridge, 
UK). The sequences of the sense and antisense primers utilized for 
amplification are described in Table 1. A dilution series of standard 
vascular samples determined the efficiency of the reaction. To normalize 
mRNA expression, the housekeeping gene β-actin was utilized. The 
mRNA relative quantification was calculated through the ΔΔCt method. 
2.11. DNA extraction, 16S rRNA gene amplification, bioinformatics 
In order to analyze the bacterial populations in the gut, fresh stools 
were collected from six animals in each group at the experimental end 
point. DNA extraction from faeces was performed with G-spin columns 
(INTRON Biotechnology) starting from 30 mg of samples resuspended in 
PBS. RNAses and proteinase K were used to treated all samples. DNA 
concentration was determined in the samples using Quant-IT PicoGreen 
reagent (Thermo Fischer) and DNA samples (about 3 ng) were used to 
amplify the V3-V4 region of 16S rRNA gene [8]. PCR products (approx. 
450 pb) included extension tails, which allowed sample barcoding and 
the addition of specific Illumina sequences in a second low-cycle number 
PCR. Individual amplicon libraries were analyzed using a Bioanalyzer 
2100 (Agilent) and a pool of samples was made in equimolar concen-
trations. The pool was further purified and quantified. The exact con-
centration estimated by real time PCR (Kapa Biosystems). Finally, the 
resulting DNA was sequenced on an Illumina MiSeq instrument with 2 ×
300 paired-end read sequencing at the Unidad de Genómica (Parque 
Científico de Madrid, Spain). 
BIPES pipeline was utilized to process the raw sequences. First, if 
containing ambiguous bases or mismatches in the primer regions, the 
barcode primers were trimmed and filtered following BIPES protocol. 
Second, we expunged any sequences with more than one mismatch in 
the 40–70 bp region at each end. Third, we used 30 Ns to concentrate the 
two single-ended sequences for the downstream sequence analysis. 
Third, we carried out an UCHIME analysis (implemented in USEARCH, 
version 6.1) to screen out and remove chimeras in the de novo mode 
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(using-minchunk 20-xn 7-noskipgaps 2). In each sample, between 
90,000 and 220,000 sequences were identified. All subsequent analyses 
were performed with 16S Metagenomics (Version: 1.0.1.0) from Illu-
mina. The sequences were then clustered into their operational taxo-
nomic units (OTU) using USEARCH with default parameters 
(USERACH61). The threshold distance was set to 0.03. Hence, when the 
similarity between two 16S rRNA sequences was 97 %, the sequences 
were classified as the same OTU. QIIME-based alignments of represen-
tative sequences were performed using PyNAST, and the Greengenes 
13_8 database was used as the template file. The Ribosome Database 
Project (RDP) algorithm was applied to classify the representative se-
quences into specific taxa using the default database. The Taxonomy 
Database (National Center for Biotechnology Information) was used for 
classification and nomenclature. Bacteria were classified based on SCFA 
end-product, as previously described [8]. Succinctly, genera were clas-
sified into more than one group correspondingly if they were defined as 
producers of multiple metabolites. Bacteria were classified according to 
their oxygen requirements with the Genomes OnLine Database (GOLD) 
[8]. The metagenomic prediction was performed by phylogenetic 
investigation of communities by reconstruction of unobserved states 
(PICRUSt). Predicted metagenomes were subsequently subjected to 
collapse predictions into Kyoto Encyclopedia of Genes and Genomes 
pathways (KEGG). The obtained data were presented as relative abun-
dance of predicted functions within the samples. The abundance of 
KEGG modules was calculated by summing the abundance of genes 
annotated to the same feature. The interest pathways were presented as 
relative abundance of predicted functions within the samples. The rest of 
the obtained data was used to analyze the variation among the groups 
represented by z-score analyses. 
2.12. Reagents 
All reagents were purchased from Merk (Barcelona, Spain) unless 
otherwise specified. 
2.13. Statistical analysis 
The Shannon, Chao, Pielou and whole observed species were calcu-
lated using QIIME (PAST 3x). Reads in each OTU were normalized to 
total reads in each sample. Only taxa with a percentage of reads > 0.001 
% were used for the analysis. Linear Discriminant Analyze (LDA) scores 
greater than 2 were displayed. Taxonomy was summarized at the genus 
level within QIIME-1.9.0 and uploaded to the Galaxy platform [44] to 
generate Linear discriminant analysis effect size (LEfSe)/cladogram 
enrichment plots where significant enrichment was considered at a P <
0.05, LDA score > 2. Results are expressed as means ± SEM of mea-
surements. The evolution of tail SBP with time was compared using the 
nested design, with treatment and days as fixed factors and the rat as a 
random factor. When the overall difference was significant comparisons 
were made using Bonferroni’s method with an appropriate error. 
Analysis of the nested design was also carried out with groups and 
concentrations to compare the concentration-response curves to 
acetylcholine. The significance of functional KEEG modules was tested 
by Wilcoxon rank sum test. The rest of the variables were compared with 
two-way factor designs, where group and treatment were fixed effect 
factors with unequal sample sizes in the different groups. When inter-
action was significant Bonferroni’s method was used for pairwise com-
parisons. P < 0.05 was considered statistically significant. 
3. Results 
3.1. Mycophenolate (MMF) treatment reduces gut dysbiosis in SHR 
The composition and diversity of bacterial communities was 
analyzed by calculating four key ecological parameters: Chao richness, 
Pielou evenness, Simpsons diversity and the number of observed species. 
In SHR low richness and diversity with no observable changes in even-
ness or the number of species were found compared to those found in 
WKY. MMF was unable to restore these parameters (Fig. 1). When the 
axonometric three-dimensional principal component analysis (PCA) at 
genus level of the bacterial community was represented, the composi-
tions of the faecal microbial communities of WKY and SHRs were found 
to be significatively different from the previously reported compositions 
[3,8]. In the PCA, the 2 clusters representing the fecal microbial com-
positions of WKY and SHR were neatly separated, indicating 2 extremely 
distinct gut microbial compositions. The cluster SHR-MMF shows 
proximity to WKY compared to SHR (Fig. 2A). The Kaiser-Meyer-Olkin 
test was 0.82, indicating a highly suitable sampling for PCA. The Bar-
lett’s test of sphericity was <0.05. The key bacterial population that was 
responsible for discriminating among groups was the the genus Oscil-
lospira (loading 0.83). The percentage of bacteria from the phylum Fir-
micutes was significantly higher in SHR than in WKY, while the 
proportions of Actinobacteria and Bacteroidetes were decreased in SHR 
when comparing to other groups. MMF restored bacteria from the phyla 
Table 1 
Primers for real-time RT-PCR.  
mRNA targets Descriptions (Gene ID) Forward Reverse 
TNF-α tumor necrosis factor-alpha (24835) ACGATGCTCAGAAACACACG CAGTCTGGGAAGCTCTGAGG 
IL-6 interleukin-6 (24498) GATGGATGCTTCCAAACTGG AGGAGAGCATTGGAAGTTGG 
IL-10 interleukin-10 (25325) GAATTCCCTGGGAGAGAAGC GCTCCACTGCCTTGCTTTTA 
IL-17a interleukin-17a (301289) CTTCACCTTGGACTCTGAGC TGGCGGACAATAGAGGAAAC 
IL1В Interleukin-1β (24494) GTCACTCATTGTGGCTGTGG GCAGTGCAGCTGTCTAATGG 
CCL2 C-C Motif Chemokine Ligand 2 (24770) CCTCCACCACTATGCAGGTC CAGCCGACTCATTGGGATCA 
IFNϒ interferon gamma (29197) GCCCTCTCTGGCTGTTACTG CCAAGAGGAGGCTCTTTCCT 
T-bet T-bet (303496) CCACCAGCACCAGACAGAGA AACATCCTGTAATGGCTCGTG 
CD3 Cluster of differentiation 3 (25710) CGTCCGCCATCTTGGTAGAGAGAGCAT CTACTGCTGTCAGGTCCACCTCCAC 
CD11b Cluster of differentiation 11b (25021) GAGAACTGGTTCTGGCTTGC TCAGTTCGAGCCTTCTT 
FOXP3 forkhead box P3 (317382) AGGCACTTCTCCAGGACAGA CTGGACACCCATTCCAGACT 
RORϒ ROR-gamma 1(9885) GCCTACAATGCCAACAACCACACA TGATGAGAACCAAGGCCGTGTAGA 
Occludin Occludin (83497) AGCCTGGGCAGTCGGGTTGA ACACAGACCCCAGAGCGGCA 
Muc2 mucin-2 (24572) CGATCACCACCATTGCCACTG ACCACCATTACCACCACCTCAG 
MUC3 mucin-3 (687030) CACAAAGGCAAGAGTCCAGA AGTGTCCTTGGTGCTGCTGAATG 
ZO-1 zonula occludens-1 (292994) GCCAGCCAGTTCCGCCTCTG AGGGTCCCGGGTTGGTG 
Th tyrosine hydroxylase (25085) GATTGCTACCTGGAAGGAGGT AGTCCAATGTCCTGGGAGAAC 
RNP1-2 alpha defensin RNP1-2 (613220) GGACGCTCACTCTGCTTACC TGGATTCTTCTTGGTCGGAG 
RNP3 alpha defensin RNP3 (498659) AAGAGCGCTGTGTCTCTTGC CAACAGAGTCGGTAGATGCG 
RNP4 alpha defensin RNP4 (286958) TCTGCTCATCACCCTTCTCC AACAGAGACGGTAGATGCGG 
RNP5 alpha defensin RNP5 (28699) ACCAGGCTTCAGTCATGAGG CATCCCATTGGTTCTTGGTC 
GAPDH glyceraldehyde-3-phosphate dehydrogenase (28383) GTCGGTGTGAACGGATTT ATGGGTTTCCCGTTGATG  
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Firmicutes and Bacteroidetes to proportions similar to those from WKY 
(Table 2, Fig. 2B). The F/B ratio has been described as an indicator of 
intestinal dysbiosis [3] and in SHR was found ~3-fold elevated, being 
reduced by MMF treatment (Fig. 2B). Analyzing bacterial populations of 
interest, we found a significant reduction in the proportions of acetate- 
and propionate-producing bacteria, and higher levels of 
lactate-producing bacteria, with no significant differences present in the 
populations of butyrate-producing bacteria, in SHR compared to WKY. 
MMF restored the level of acetate- and lactate- producing bacteria and 
also, it was able to elevate the butyrate-producing bacteria (Fig. 2C). 
Furthermore, the populations of strict anaerobic bacteria were signifi-
cantly depleted in SHR compared with WKY group, but no significant 
differences in strict aerobic bacteria were observed (Fig. 2D). MMF was 
able to restore the shift in anaerobic bacteria populations. 
In Fig. 3A is displayed the alteration in bacterial taxa (class, order, 
family, and genus) observed in SHR through LEfSe. Relevant shifts in 
bacterial taxa were detected, where the relative abundance of 51 taxa 
were increased (green) and 19 taxa were decreased (red) in WKY 
compared to SHR. MMF-treated SHR also triggered substantial changes 
in the microbiota taxa compared to SHR group, where the relative 
abundance of 68 taxa were increased (green) and 12 taxa was decreased 
Fig. 1. Effects of Mycophenolate mofetil (MMF) in ecological parameters of the gut microbiota from spontaneously hypertensive rat (SHR). The microbial DNA from 
fecal samples was analyzed by 16S rRNA gene sequencing. In order to assess general differences of fecal microbial composition amongst all experimental groups, 
richness, evenness, diversity, and observed species were examined. Values are represented as means ± SEM. n = 6 rats per experimental group. *P < 0.05 significant 
differences compared with WKY. 
Fig. 2. Mycophenolate mofetil (MMF) induces different behaviours from the gut microbiota of spontaneously hypertensive rats (SHR). The microbial DNA 
from faecal samples was analyzed by 16S rRNA gene sequencing. A) Principal coordinate analysis in the gut microbiota from all experimental groups. B) Phylum 
breakdown of the six most abundant bacterial communities in the faecal samples was obtained from all experimental groups and Firmicutes/Bacteroidetes ratio (F/B 
ratio) was calculated as a biomarker of gut dysbiosis. C) Relative proportion of lactate-, butyrate-, acetate- and propionate-producing bacteria expressed as relative 
proportions of total Bacteria. D) Relative proportion of anaerobic and aerobic bacteria in the gut microbiota in Wistar Kyoto rats (WKY), untreated SHR and SHR 
treated with MMF (SHR-MMF). n = 6. Values are represented as means ± SEM. *P < 0.05 and **P < 0.01 significant differences compared with WKY. #P < 0.05 and 
##P < 0.01 significant differences compared with untreated SHR. 
Table 2 
Effects of mofetil mycophenolate (MMF) in spontaneously hypertensive rats 
(SHR) on phyla changes in the gut microbiota (% of total reads).  
Phylum WKY 
(n = 6) 
SHR 
(n = 6) 
SHR + MMF 
(n = 6) 
Firmicutes 72.6 ± 5.0 86.3 ± 1.4* 66.1 ± 8.5# 
Proteobacteria 11.0 ± 4.8 5.8 ± 1.4 11.4 ± 4.7 
Bacteroidetes 5.1 ± 1.4 1.7 ± 0.3* 7.5 ± 2.4# 
Actinobacteria 6.1 ± 1.0 3.5 ± 0.6* 3.4 ± 1.5 
Verrucomicrobia 1.9 ± 0.6 0.8 ± 0.3 8.6 ± 5.5 
Tenericutes 0.5 ± 0.1 0.5 ± 0.1 0.8 ± 0.3 
Others 1.7 ± 0.6 0.9 ± 0.1 1.4 ± 0.4 
Values are expressed as mean ± SEM. 
* P < 0.05 compared with the Wistar Kyoto (WKY) group. 
# P < 0.05 compared with the SHR group. 
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Fig. 3. Distinct shifts in the gut microbiota between Wistar Kyoto rats (WKY) and spontaneously hypertensive rats (SHR) and the Mycophenolate mofetil (MMF) 
treatment. A) Comparisons of microbiome changes in WKY versus SHR. (green bars represent WKY-enriched taxa, red bars represent SHR-enriched taxa). B) Com-
parisons of microbiome changes in SHR versus SHR-MMF (green bars represent SHR-MMF -enriched taxa, red bars represent SHR-enriched taxa). Linear discriminant 
analysis effect size (LEfSe) identified significantly different bacterial taxa enriched in each cohort at LDA Score > 2, P < 0.05. n = 6 rats per experimental group in 
each comparison (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article). 
Fig. 4. Mycophenolate mofetil (MMF) induces genera shifts in the gut microbiota composition in spontaneously hypertensive rats (SHR). A) The heatmap colors 
represent the relative percentage of microbial genus assigned within each sample in SHR experiment. B) The relative abundance of Lactobacillus and Sutterella genus 
in SHR. Values are expressed as mean ± SEM (n = 6). *P < 0.05 and **P < 0.01 compared with WKY rats. #P < 0.05 and ##P < 0.01 significant differences compared 
to untreated SHR group. 
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(red) (Fig. 3B). In the heat map was analyzed the relative expression of 
the eleven major genera found in SHR (Fig. 4A, B). Several authors have 
described the ability of certain bacteria to modulate the immune system, 
such as Lactobacillus, Bifidobacterium, Sutterella [45–47], among others. 
We found higher amounts of the genus Lactobacillus (from the Lactoba-
cillaceae family) in SHR, being MMF treatment able to normalize them 
(Fig. 4B). In addition, no changes were found in the genus Sutterella, 
which at low levels within the gut microbiome is associated with gut 
immune homeostasis [47], when it was compared to the WKY group 
(Fig. 4B), but the MMF treatment was able to elevate it. Similarly, MMF 
reduced Clostridium content in SHR, being without significant effect in 
Akkermansia proportion, which was reduced in SHR compared to WKY 
(Fig. 4B). 
3.2. Mycophenolate (MMF) induces an alteration in the functional profile 
of bacterial pathways in the intestinal microbiota of SHR 
The functional alterations in the gut microbiota were evaluated 
across experimental groups and expressed as Z-score using KEGG data-
base (Fig. 5). A great number of changes were found when the hyper-
tensive group was compared to their control group. Nineteen KEGG 
modules were differentially modulated between WKY vs SHR (adjusted P 
value <0.05, Wilcoxon rank sum test). The MMF treatment induced a 
broad number of alterations in the functional pathways, in particular, in 
SHR-MMF forty-five pathways were found modulate when compared to 
SHR. Especially, pathways related to fatty acid metabolism were found 
changed in the SHR group (Fig. 5A). Moreover, significant differences 
were observed among groups in KEGG modules, when PCA was per-
formed. A clear separation cluster was found between WKY vs SHR 
(Fig. 5B). Analyzing the role of MMF treatment on the functional al-
terations we found a clear separation among SHR-MMF vs WKY and vs 
SHR, showing a different functional bacterial profile induced by MMF. 
3.3. Mycophenolate (MMF) improves intestinal integrity, endotoxemia, 
α-defensins production, and changed MLNs T cells in SHR 
Hypertension is associated with a decrease in gut tight junction 
proteins expression levels, a raise in permeability and gut pathology 
[48]. We observed lower mRNA levels of barrier-forming junction pro-
teins zonula occludens-1 (ZO-1) and occludin in colonic samples from 
SHR compared to WKY (Fig. 6A). MMF successfully restored occludin 
and ZO-1 expression levels in colon, pointing to an improvement in the 
barrier function. Additionally, high gut permeability in adult hyper-
tensive SHR is correlated with low numbers of goblet cells [49]. Goblet 
cells excrete mucins, protecting the gut from pathogen invasion, and 
thus, regulating the gut immune response [50]. We have also found a 
downregulation of mucin (MUC)-2 transcripts in hypertensive groups, 
which was unaffected by MMF. No changes in MUC-3 in SHR compared 
to WKY were observed, but treatment with MMF increased its gene 
expression (Fig. 6A), pointing to a lower gut permeability. We quantified 
plasma endotoxin levels, and found them significantly increased in SHR 
comparing with WKY group (Fig. 6B). Remarkably, the long-term 
treatment with MMF decreased endotoxemia in SHR (Fig. 6B). Our re-
sults suggest an increase in intestinal permeability in SHR that would 
allow bacterial components (e.g., LPS) to enter the blood stream. 
Moreover, the high mRNA concentrations of the colonic 
pro-inflammatory cytokines tumor necrosis factor-α (TNF-α) and IL-6 
(Fig. 6C) in SHR were normalized by MMF administration. 
Santisteban et al., [49] showed that the increase in the sympathetic 
nerve activity to the gut leads to alteration of gut junction proteins in 
SHR. We found an increase in the expression of tyrosine hydroxylase 
(TH), a crucial enzyme for the generation of noradrenaline, in the gut 
from SHR compared to WKY group, which was abolished by chronic 
MMF treatment (Fig. 6D). These results suggest that a reduction in the 
sympathetic tone in the gut could be associated with the possitive effects 
of MMF in the gut. 
Epithelial intestinal cells are able to produce α-defensins, cysteine- 
rich cationic peptides with antibiotic activity against a broad range of 
microorganisms [51], to keep a stable composition of intestinal micro-
biota [52]. Our experiment in SHR shows a reduction in the α-defensin 
RNP1-2 expression levels, and increased mRNA levels of RNP3 and 
RNP4, without significant change of RNP5 in colon in comparison with 
the WKY group. MMF restored the expression levels of defensins to levels 
similar to those found in control groups in both experiments (Fig. 7). 
As already explained, bacteria can translocate through the intestinal 
barrier leading to the activation of machrophages and dendritic cells and 
their migration to draining lymph nodes of the lower intestinal tract 
when under altered gut mucosal integrity [12]. These CX3CR1+ cells 
can also present soluble antigens to naïve CD4 + T cells, causing T cell 
activation. In our experiments, the number of total lymphocytes in MLNs 
Fig. 5. Mycophenolate mofetil (MMF) induced changes in the gut microbial functions in spontaneously hypertensive rats (SHR). A) The average abundance 
of KEGG modules differentially enriched in all experimental groups expressed as Z-score. B) Principal coordinate analysis in the predictive functional profiling of 
microbial communities. n = 6 rats per experimental group in each comparison. ##P < 0.01 significant differences compared with untreated SHR group. 
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was elevated in SHR compared to WKY. MMF treatment normalized the 
content in lymphocytes in MLNs in both hypertensive models (Fig. 8A). 
The percentage of Treg was reduced in SHR group being it normalized 
by MMF treatment. The percentage of Th17 lymphocytes was higher in 
MLNs from SHR compared to WKY group. However, MMF was unable to 
change Th17 populations in MLNs (Fig. 8B). The level of cytokines 
produced by Treg (IL10) was found reduced in SHR, being elevated by 
the MMF treatment. IL17, which is mainly produced by Th17 was found 
elevated in SHR, and MMF was able to normalize it (Fig. 8C). 
3.4. Mycophenolate mofetil (MMF) reduces BP, improves vascular nitric 
oxide (NO) pathway, and reduced oxidative stress and inflammation in 
aorta and brain 
As was described previously by Tipton et al., [27] in SHR, chronic 
MMF treatment showed a progressive reduction in SBP (Fig. 9A), which 
was significative after week 2 of treatment, reaching a total reduction in 
SHR of 29.5 ± 5.9 mmHg. However, MMF was unable to significant 
reduce left ventricular hypertrophy in SHR (Fig. 9B). Aortae from hy-
pertensive rats displayed a markedly reduced endothelium-dependent 
vasodilator responses to acetylcholine compared to control. SHR re-
sponses were improved (~ 15 %) after MMF treatment (Fig. 9C). The 
incubation with L-NAME in the organ bath impeded the normal relax-
ation induced by acetylcholine in all experimental groups, suggesting 
NO to be involved in this relaxation (data not shown). Additionally, no 
differences were found among groups in the endothelium-independent 
vasodilator responses to the NO donor sodium nitroprusside in aortic 
rings, discarding changes in the NO pathway in smooth muscle (data not 
shown). The presence of apocynin in the organ bath increased the 
relaxation response to acetylcholine in untreated SHR until reaching 
similar relaxation percentages to those found in control group (data not 
shown), pointing to the, at least, partial involvement of the increased 
NADPH oxidase activity in the impaired relaxation to acetylcholine in 
aorta from SHR. In fact, the NADPH oxidase activity was found reduced 
in the groups treated with MMF compared to the control groups 
(Fig. 9D). In addition, aortic segments from SHR displayed a strong in-
crease in ROS contents (Fig. 9E), expressed as red staining to ethidium in 
vascular wall (~ 27 %). The MMF treatments normalized the vascular 
ROS in both experimental models (Fig. 9E). 
The infiltration of T cells in aorta was analyzed using the mRNA 
levels of transcription factor FoxP3, retinoid-related orphan receptor-γ 
(RORγ), and T-bet as markers of accumulation of Treg, Th17, and Th1, 
respectively (Fig. 10A). Increased Th17 and Th1 cells and reduced Tregs 
infiltration was shown in aorta from SHR. MMF treatment normalized T 
Fig. 6. Mycophenolate mofetil (MMF) induces improvement of gut integrity and inflammation, and gut sympathetic tone in spontaneously hypertensive rats (SHR). 
A) mRNA levels of occludin, zonula occludens-1 (ZO-1), mucin (MUC)-2, and MUC-3 in colon. B) Levels of plasma endotoxin (endotoxin units/mL (EU/mL). C) 
Colonic mRNA levels of pro-inflammatory cytokines, tumor necrosis factor-α (TNF-α) and interleukin (IL)-6. D) Colonic tyrosine hydroxylase (TH) expression. Values 
are expressed as mean ± SEM (n = 7–9). *P < 0.05 and **P < 0.01 compared with WKY group. #P< 0.05 and ##P< 0.01 significant differences compared to 
untreated SHR group. 
Fig. 7. Mycophenolate mofetil (MMF) induces an improvement in α-defensins production in spontaneously hypertensive rats (SHR). mRNA levels of 
α-defensins (RNP1.2, RNP3, RNP4, and RNP5) in colon from Wistar Kyoto rats (WKY), untreated SHR (SHR) and SHR treated with MMF (SHR + MMF). Values are 
expressed as mean ± SEM. *P < 0.05 and **P < 0.01 compared with WKY. #P < 0.05 and ##P < 0.01 compared with the untreated SHR group. 
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cells infiltration in SHR, Interestingly, linked to T cells infiltration, the 
mRNA levels of the proinflammatory cytokines IL-17a and IFN-γ were 
higher in SHR (Fig. 10B), as compared to WKY group. Again, the 
treatment with MMF restored the mRNA levels of these cytokines, 
whereas increased IL-10 content in aortic homogenates from SHR. 
We found that ROS production (Fig. 11A), NADPH oxidase activity 
(Fig. 11B) and the mRNA levels of CCL2 and CD11b (Fig. 11C) in brain 
PVN were higher in the SHR group than those found in the WKY group, 
and were reduced by MMF treatment. In addition, the mRNA levels of 
pro-inflammatory cytokines (TNF-α, IL-1β, IL-6, and IL-17a) (Fig. 11D) 
were also increased in SHR and decreased by MMF. 
Fig. 8. Mycophenolate (MMF) improves T 
cell profile at mesenteric lymph nodes 
(MLNs) in spontaneously hypertensive rats 
(SHR). A) Total T cells (CD4+CD45+), and, B) 
regulatory T cells (Treg; CD4+ FoxP3+), and T 
helper (Th)-17 (CD4+ IL17a+) cells in MLNs 
from all experimental groups. C) Concentration 
of IL-17a and IL-10 was measured by ELISA in 
lymphocyte conditioned media from MLNs. 
Values are expressed as mean ± SEM. *P < 0.05 
and **P < 0.01 compared with WKY group. #P 
< 0.05 and ##P < 0.01 significant differences 
compared with untreated SHR group.   
Fig. 9. Mycophenolate mofetil (MMF) reduces blood pressure and endothelial function in aorta from spontaneously hypertensive rats (SHR). A) Time course of 
systolic blood pressure (SBP) measured by tail-cuff plethysmography. B) Ratio Left ventricle/tibia length (mg/cm). C) Endothelium-dependent relaxation induced by 
acetylcholine (ACh) in aortas precontracted by phenylephrine. NADPH oxidase activity (D), and in situ intracellular ROS (E) in aorta from all experimental groups. 
Values are expressed as mean ± SEM (n = 8). *P < 0.05 and **P < 0.01 significant differences compared with WKY. #P < 0.05 and ##P < 0.01 significant differences 
compared with untreated SHR group. 
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4. Discussion 
The principal original findings of this study are as follows: 1) Chronic 
MMF treatment decreases gut dysbiosis in hypertensive SHR; 2) Shifts in 
gut microbiota composition induced by MMF were linked to the 
enhancement of gut integrity and the normalization of colonic 
α-defensins production, and to the reduction in neuroinflammation and 
gut sympathetic drive. 
Numerous authors have established the link between gut dysbiosis, 
immune system and hypertension [3,5,6,11,53]. Our results are 
consistent with what was previously described [18,19,21], being MMF 
able to induce a reduction in BP in SHR. In addition, MMF improved the 
endothelial dysfunction joined to a reduction in ROS production as was 
described by Tian et al. [20]. Furthermore, as already was described 
[27] MMF treatment induced a modulation in the aortic immune cell 
infiltration inducing a reduction in the pro-inflammatory cytokines 
profile. 
Several studies have described the ability of immunomodulatory 
drugs to modulate the gut microbiota inducing dysbiosis [54] or 
improving the disbiotic condition found in several pathologies [55]. 
Fig. 10. Mycophenolate mofetil (MMF) induces 
changes in T cell infiltration in the vascular wall 
from spontaneously hypertensive rats (SHR). 
(A) T-cell infiltration in aortas from all experi-
mental groups was measured by mRNA levels of 
T helper (Th)17; RORγ), regulatory T cells 
(Treg; FoxP3), and Th1 (T-bet). (B) Cytokine 
content in aorta from all experimental groups 
was analyzed by mRNA levels of interleukin (IL) 
17a, IL10, and INFγ. Values are expressed as 
mean ± SEM. *P < 0.05; **P < 0.01 significant 
differences compared with WKY or CTR. #P <
0.05; ##P < 0.01 significant differences 
compared with untreated SHR or DOCA.   
Fig. 11. Mycophenolate mofetil (MMF) reduces immune cells infiltration, neuroinflammation, and NADPH oxidase activity in the paraventricular nucleus (PVN) of 
the hypothalamus in spontaneously hypertensive rats (SHR) A) CM-H2DCFDA-detected intracellular ROS in absence and presence of NADPH oxidase inhibitor 
apocynin (50 μM) (n = 4–6). B) NADPH oxidase activity measured by DHE fluorescence measured in the microplate reader in homogenates from brain PVN. (n = 5) 
C) mRNA levels of C-C Motif Chemokine Ligand 2 (CCL2) and cluster of differentiation molecule 11B (CD11b). D) mRNA levels of pro-inflammatory cytokines, tumor 
necrosis factor α (TNFα), interleukin (IL)6, IL-1β and IL17a in homogenates from brain PVN of SHR. Values are expressed as mean ± SEM (n = 7–9). *P < 0.05 and 
**P < 0.01 significant differences compared with WKY. #P < 0.05 and ##P < 0.01 significant differences compared with untreated SHR. 
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Tacrolimus, a macrolide used for maintenance of immunosuppression in 
organ transplant recipients, can raise BP, being the elevation induced by 
tacrolimus dependent on its effect on the intestinal microbiota [28]. Last 
year it was reported how gut dysbiosis is displayed in diverse experi-
mental models of hypertension [3,5,7–9,55–58] with different charac-
teristics in each model. Our results are in agreement with the key known 
characteristics of dysbiotic microbiota described in SHR [3,5,7–9,11], 
such as, a low richness and diversity, a high F/B ratio, and a decrease in 
acetate- and propionate-producing bacteria, with higher proportions of 
lactate-producing bacteria. MMF tended to normalize the gut micro-
biota, regulating the F/B ratio and SCFAs-producing microorganisms. 
BP lowering effects of MMF have been associated with decreased 
circulating and renal T cells in SHR, although MMF reduced both T cell 
subtypes, Th17 and T-regulatory (Tregs) [27]. However, we found 
increased Tregs and IL10 (the main cytokine produced from Treg) in 
both MLNs and aorta from MMF treated rats, which could contribute to 
their antihypertensive effects, since IL10 released by Tregs improves 
endothelial function and reduces BP in hypertensive mice [42]. Several 
authors have described the ability of certain SCFA, as butyrate, to 
modulate the immune system. Concretely, butyrate is able to induce an 
elevation in Treg populations [59]. We found an expansion in 
butyrate-producing bacteria induced by MMF treatment in SHR, which 
could be involved in the higher numbers of Treg and IL-10 found in MLN 
and aorta from SHR-MMF group. Surprisily, MMF did not reduce Th17 
population in MLNs, taken into account the direct effect of MPA, the 
active form of MMF, inhibiting IL-17 expression [24]. The lack of 
inhibitory effect induced by MMF in this gut secondary lymph organ 
could be related to the elevation in the genus Sutterella, which has been 
described to increase Th17 population [60], found in feces from 
SHR-MMF group. However, MMF reduced Th17 infiltration in aorta, 
leading to lower IL17, which could contribute to improve endothelial 
dysfunction [5]. In addition, the high proportions of Lactobacillus ssp. 
found in SHR were also normalized by the MMF treatment. This is an 
important beneficial effect because Lactobacillus ssp. has been shown to 
elevate certain pro-inflammatory cytokines as IL-6, TNFα or INFγ [61, 
62]. Moreover, theses changes in the gut microbiota also entailed 
modulation in the bacterial synthesis pathways, found a clear different 
predictive functional profile between WKY vs SHR. In particular, in SHR, 
MMF induced an alteration in the fatty acid pathways. 
Multiple possibilities whereby MMF might provoke shifts in gut 
microbiota were found. It has been repeatedly shown how changes in the 
host health status are complemented by changes in the composition of 
gut microbiota. Accordingly, the microbiota could be adapted to BP 
reduction, shifting to a composition similar to normotensive rats. 
Nonetheless, we previously demonstrated that hydralazine, which 
normalized BP in SHR, was unable to improve dysbiosis [8], ruling out 
the hypothesis that gut microbiota adapted to normotensive conditions. 
Shifts in the composition of gut microbiota have been linked to gut 
integrity [4]. The mammalian digestive tract epithelial cells create a 
tight barrier in the gut, contributing to the hypoxic environment of the 
lumen. Damage to this barrier makes the environment less hypoxic, 
conducive to aerobic bacterial growth [63]. In the SHR was found a 
reduction in the mRNA expression of tight junction proteins, ZO-1 and 
Occludin, being normalized by the MMF treatment. Increased intestinal 
permeability in adult hypertensive SHR has been related to reduced 
goblet cells [49]. These cells produce mucins, which protect the gut from 
pathogen invasion, were downregulated in hypertensive groups, and 
treatment with MMF increased its gene expression, suggesting that MMF 
reduces gut permeability. In fact, MMF inhibited the LPS translocation 
to the systemic circulation. In addition, intestines of angiotensin 
II-hypertensive mice and SHR [4,8] were significantly less hypoxic and 
presented increased aerobic bacteria in feces, due to a reduction in the 
epithelium barrier integrity. We also found a reduction in the pop-
ulations of anaerobic bacteria in feces from SHR, which were linked to a 
loss of gut integrity. MMF-treated SHR displayed an increased colonic 
integrity and a proportion of strict anaerobic bacteria similar to WKY 
rats. The data reinforces the essential role of gut integrity in the 
composition of intestinal microbiota. Furthermore, intestinal epithelial 
cells and Paneth cells secrete antimicrobial peptides, such as defensins, 
which selectively kill Gram-positive bacteria [64–67]. Components of 
bacteria present in the microbiota, such as LPS, are recognized by 
Toll-like Receptors expressed by these intestinal cells which trigger 
defensins production and secretion. We found changes in the expression 
levels of defensins in colonic samples from our hypertensive model 
compared to WKY group, which might also be involved in changes in 
microbiota found in SHR. MMF restored defensins expression to become 
similar to normotensive rats. 
These results are consistent with Santisteban et al., [49], evidencing 
the existence of an increased gut sympathetic drive (higher TH levels) 
linked to microbial dysbiosis and the lost of gut integrity in hypertensive 
animals. Robles-Vera et al. [8], demonstrated that reduction of sympa-
thetic activity in the colon induced by losartan improved gut integrity 
and reduced gut dysbiosis, whereas hydralazine (that increased gut 
sympathetic drive) was uncapable of restoring gut integrity and micro-
biota composition. We also found increased mRNA levels of TH in the 
colon from SHR, which were normalized by MMF treatment. In recent 
years, the hypothesis that establishes the existence of a brain-gut 
communication driven by the sympathetic system has gained preva-
lence. Central administration of a modified tetracycline inhibited 
microglial activation, normalised sympathetic activity, attenuated 
pathological alterations in gut wall, restored certain gut microbial 
communities altered by angiotensin II and reduced BP [68]. Santisteban 
et al. [49], observed enhanced gut-neuronal communication in hyper-
tension originating from the PVN of the hypothalamus and presenting as 
increased sympathetic drive to the gut. In brain, angiotensin II via an 
AT1 receptor mechanism activates the sympathetic outflow by stimu-
lation of the NADPH oxidase-dependent ROS production [69]. In brains 
from SHR, we observed a high NADPH oxidase activity-driven ROS 
production, and a higher pro-inflammatory cytokine (TNF-α, IL-1β, and 
IL-6) expression rate than in WKY. The increased sympathetic activity 
also affects the bone marrow (BM) resulting in an increase in inflam-
matory cells, which migrate to the PVN and enhance neuroinflammation 
[48,49]. Accordingly, we found increased inflammation in brain PVN 
from SHR, linked to increased CCL2 expression levels, which facilitate 
BM cells entering the brain’s parenchymal space; CD11b, a macrophage 
marker; and IL-17a, mainly produced by Th17 cells, that might 
contribute to neuroinflammation. MMF reduced immune cells infiltra-
tion, neuroinflammation, and NADPH oxidase activity in brain areas of 
cardiovascular control such as PVN. Our results are in agreement with 
the reduced brain macrophage/glial activation induced by MMF in 
stroke-prone SHR [70]. The brain changes induced by MMF in SHR 
might reduce the sympathetic excitation, lending to lower gut sympa-
thetic drive (lower colonic TH expression). Additionally, the reduced 
IL-17 levels in the intestine from hypertensive rats treated with MMF can 
act on sympathetic somata and distal neurites to reducing neurite 
outgrowth, and improving the neuroanatomical plasticity that accom-
panies inflammation [71]. The gut sympathetic tone is a crucial modu-
lator of gut barrier integrity and microbiota composition [8,41]. Our 
results also support this hypothesis because MMF, that reduced colonic 
TH, improved gut integrity and gut dysbiosis in SHR. 
5. Conclusions 
We have found for the first time that MMF reduces gut dysbiosis in 
SHR. This appears to be linked to its ability to improve gut integrity due 
to reduced sympathetic drive in the gut associated to the decreased brain 
neuroinflammation. 
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Gómez, A. Zarzuelo, J. Gálvez, J. Tamargo, F. Pérez-Vizcaíno, J. Duarte, 
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M. Gómez-Guzmán, R. Jiménez, M.K. Raizada, J. Duarte, Critical role of the 
interaction gut microbiota-sympathetic nervous system in the regulation of blood 
pressure, Front. Physiol. 10 (2019) 231. 
[42] M. Kassan, M. Galan, M. Partyka, M. Trebak, K. Matrougui, Interleukin-10 released 
by CD4(+)CD25(+) natural regulatory T cells improves microvascular endothelial 
function through inhibition of NADPH oxidase activity in hypertensive mice, 
Arterioscler. Thromb. Vasc. Biol. 31 (11) (2011) 2534–2542. 
[43] M. Romero, M. Toral, I. Robles-Vera, M. Sánchez, R. Jiménez, F. O’Valle, 
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